GammaDelta Therapeutics announced as winner of the 2018 Outstanding Achievement Award at the OBN Annual Awards Ceremony.

Mike Owen, PhD

Board Member

Mike Owen has worked in biomedical research, and in the pharmaceutical and biotechnology industries for nearly 40 years. In addition to GammaDeltaTherapeutics, he serves as a director on five boards. He is the Chairman of OssianixInc, a privately held biotechnology company. He is on the boards of Zealand PharmaA/S, Avacta Group plc, ReNeuron plc and BliNK Biomedical SAS. Dr Owen is also an advisor to the CRT Pioneer Fund and Abingworth LLP, and is Chairman of ReNeuron’s and Avacta’s SABs. Prior to board services, Dr Owen co-founded and served as the first CSO of Kymab Ltd, a biopharmaceutical company. Prior to co-founding Kymab, Dr Owen worked for GSK where he was SVP and Head of Research for Biopharmaceuticals R&D. Dr Owen received a BA degree from Oxford University in 1973 and a PhD from Cambridge University in 1976. He was elected a member of the European Molecular Biology Organisation and a Fellow of the Academy of Medical Sciences.